Brind.

Gilead Sciences' drug Trodelvy received marketing authorization from the European Commission for use in EU member states.

1 report, 1 independent Updated Jun 25

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Gilead Sciences European Commission

Keep exploring

The entities involved

Gilead Sciences
American company
- Amgen and Gilead Sciences are two companies that compete within the biotech industry.Sun 11:22
- Gilead Sciences is commercializing medicines in Europe, with Anu Osinusi as VP of Clinical Development and Cynthia Levy supporting IDEAL results for Livdelzi.Fri 16:08
European Commission
executive branch of the European Union
- The EU plans a deeper partnership with Canada while US tariffs escalate the ongoing trade feud.Sun 20:53
- Mureșan supports the EU's global vision as the Commission centers the bloc in Brussels amid Canada's geopolitical shift.Sun 20:53

Coverage

Newest first; wire copies grouped

Jun 25pmlive.com